109 related articles for article (PubMed ID: 28739143)
1. Prediction of time-integrated activity coefficients in PRRT using simulated dynamic PET and a pharmacokinetic model.
Hardiansyah D; Attarwala AA; Kletting P; Mottaghy FM; Glatting G
Phys Med; 2017 Oct; 42():298-304. PubMed ID: 28739143
[TBL] [Abstract][Full Text] [Related]
2. Treatment planning in PRRT based on simulated PET data and a PBPK model. Determination of accuracy using a PET noise model.
Hardiansyah D; Guo W; Attarwala AA; Kletting P; Mottaghy FM; Glatting G
Nuklearmedizin; 2017 Feb; 56(1):23-30. PubMed ID: 27885372
[TBL] [Abstract][Full Text] [Related]
3. The role of patient-based treatment planning in peptide receptor radionuclide therapy.
Hardiansyah D; Maass C; Attarwala AA; Müller B; Kletting P; Mottaghy FM; Glatting G
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):871-880. PubMed ID: 26577941
[TBL] [Abstract][Full Text] [Related]
4. Time-integrated activity coefficient estimation for radionuclide therapy using PET and a pharmacokinetic model: A simulation study on the effect of sampling schedule and noise.
Hardiansyah D; Guo W; Kletting P; Mottaghy FM; Glatting G
Med Phys; 2016 Sep; 43(9):5145. PubMed ID: 27587044
[TBL] [Abstract][Full Text] [Related]
5. Optimized Peptide Amount and Activity for ⁹⁰Y-Labeled DOTATATE Therapy.
Kletting P; Kull T; Maaß C; Malik N; Luster M; Beer AJ; Glatting G
J Nucl Med; 2016 Apr; 57(4):503-8. PubMed ID: 26678617
[TBL] [Abstract][Full Text] [Related]
6. Single-time-point estimation of absorbed doses in PRRT using a non-linear mixed-effects model.
Hardiansyah D; Riana A; Beer AJ; Glatting G
Z Med Phys; 2023 Feb; 33(1):70-81. PubMed ID: 35961809
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity Analysis of a Physiologically Based Pharmacokinetic Model Used for Treatment Planning in Peptide Receptor Radionuclide Therapy.
Hardiansyah D; Begum NJ; Kletting P; Mottaghy FM; Glatting G
Cancer Biother Radiopharm; 2016 Aug; 31(6):217-24. PubMed ID: 27403777
[TBL] [Abstract][Full Text] [Related]
8. Comparison of renal uptake of 68Ga-DOTANOC PET/CT and estimated glomerular filtration rate before and after peptide receptor radionuclide therapy in patients with metastatic neuroendocrine tumours.
Kaewput C; Vinjamuri S
Nucl Med Commun; 2016 Dec; 37(12):1325-1332. PubMed ID: 27612032
[TBL] [Abstract][Full Text] [Related]
9. The Influence of Early Measurements Onto the Estimated Kidney Dose in [(177)Lu][DOTA(0),Tyr(3)]Octreotate Peptide Receptor Radiotherapy of Neuroendocrine Tumors.
Delker A; Ilhan H; Zach C; Brosch J; Gildehaus FJ; Lehner S; Bartenstein P; Böning G
Mol Imaging Biol; 2015 Oct; 17(5):726-34. PubMed ID: 25790773
[TBL] [Abstract][Full Text] [Related]
10. A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours.
Forrer F; Uusijärvi H; Waldherr C; Cremonesi M; Bernhardt P; Mueller-Brand J; Maecke HR
Eur J Nucl Med Mol Imaging; 2004 Sep; 31(9):1257-62. PubMed ID: 15197500
[TBL] [Abstract][Full Text] [Related]
11. Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling schedule.
Maaß C; Sachs JP; Hardiansyah D; Mottaghy FM; Kletting P; Glatting G
EJNMMI Res; 2016 Dec; 6(1):30. PubMed ID: 27015662
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
Koukouraki S; Strauss LG; Georgoulias V; Schuhmacher J; Haberkorn U; Karkavitsas N; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2006 Apr; 33(4):460-6. PubMed ID: 16437218
[TBL] [Abstract][Full Text] [Related]
13. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic digital phantoms for accuracy assessment of image-based dosimetry in (177)Lu-DOTATATE peptide receptor radionuclide therapy.
Brolin G; Gustafsson J; Ljungberg M; Gleisner KS
Phys Med Biol; 2015 Aug; 60(15):6131-49. PubMed ID: 26215085
[TBL] [Abstract][Full Text] [Related]
15. 4D SPECT/CT acquisition for 3D dose calculation and dose planning in (177)Lu-peptide receptor radionuclide therapy: applications for clinical routine.
Kairemo K; Kangasmäki A
Recent Results Cancer Res; 2013; 194():537-50. PubMed ID: 22918781
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
17. Impact of peptide receptor radionuclide therapy on the 68Ga-DOTATOC-PET/CT uptake in normal tissue.
Giesel FL; Stefanova M; Schwartz LH; Afshar-Oromieh A; Eisenhut M; Haberkorn U; Kratochwil C
Q J Nucl Med Mol Imaging; 2013 Jun; 57(2):171-6. PubMed ID: 23370092
[TBL] [Abstract][Full Text] [Related]
18. Parametric Net Influx Rate Images of
Ilan E; Sandström M; Velikyan I; Sundin A; Eriksson B; Lubberink M
J Nucl Med; 2017 May; 58(5):744-749. PubMed ID: 27789716
[No Abstract] [Full Text] [Related]
19. Relevance of PET for pretherapeutic prediction of doses in peptide receptor radionuclide therapy.
Blaickner M; Baum RP
PET Clin; 2014 Jan; 9(1):99-112. PubMed ID: 25029939
[TBL] [Abstract][Full Text] [Related]
20. A simulation-based method to determine optimal sampling schedules for dosimetry in radioligand therapy.
Rinscheid A; Lee J; Kletting P; Beer AJ; Glatting G
Z Med Phys; 2019 Dec; 29(4):314-325. PubMed ID: 30611606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
